| Date | Title | Description |
| - | BioClin Therapeutics Announces Name Change to Rainier Therapeutics | SAN LEANDRO, Calif., November 27 2018— BioClin Therapeutics, Inc., a privately-held clinical stage drug development company focused on helping patients in the high unmet need of bladder cancer, today announced the company is changing its na... |
| - | Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell Activation | – Vofatamab activates immune changes in immunologically cold tumors and in combination increases patient response rates –
– Data from FIERCE-22 Trial in Patients with Metastatic Bladder Cancer Presented at AACR Bladder Cancer Conference –
... |
| - | Rainier Therapeutics Announces Vofatamab FIERCE-22 Data Accepted for Presentation at ESMO 2019 Annual Congress | – Updated Interim Analysis from FIERCE-22 Phase 2 Trial in Metastatic Bladder Cancer-
SEATTLE, WA and SAN LEANDRO, CA, July 29, 2019—Rainier Therapeutics, Inc., a privately held clinical stage drug development company, today announced that... |
| - | Rainier Therapeutics Presents Data on Vofatamab in Patients with Advanced Urothelial Cell Carcinoma (Bladder Cancer) Previously Treated with Chemotherapy at ASCO GU 2019 | – Preliminary data from FIERCE-21 Phase 2 trial highlighted in oral presentation supports advancement to pivotal study –
– Single agent activity and long-term treatment duration demonstrated–
SAN LEANDRO, Calif., February 15, 2019—Rainier... |
| - | Rainier Therapeutics Announces Appointment of Gary Christianson as Chief Technical Officer | SAN LEANDRO, Calif., May 1, 2019—Rainier Therapeutics, Inc., a privately held clinical stage drug development company, today announced the appointment of Gary Christianson, PE, as Chief Technical Officer.
Mr. Christianson brings more than ... |
| - | Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder ... | -Targeted antibody elicits responses in both FGFR3 wild-type and mutant/fusion patients-
-Favorable tolerability and safety profile and prolonged treatment duration-
– Results presented at America Society of Oncology (ASCO) Annual Meeting... |
| - | Rainier Therapeutics Announces Vofatamab Data Accepted for Presentation at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting | -FIERCE-21 and FIERCE-22 Phase 2 Trials in Metastatic Bladder Cancer
SAN LEANDRO, Calif., April 25, 2019—Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that abstracts related to trials... |
